Axsome Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Axsome Therapeutics (US): 2 reconciled FDA prescription therapies, $167.4M 2024 CMS Part D & Medicaid spend, and $1,150 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2043-01-01
2024 CMS Total Public Spend$167.4M
2024 Medicare Part D Spend$77.1M
2024 Medicaid Spend$90.3M
California HCAI SB 17 FilingsSpecialty launch notice ($1,150 intro WAC)